Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 300.2 DKK -3.04% Market Closed
Market Cap: 1.3T DKK
Section:
 

Relative Value

The Relative Value of one NOVO B stock under the Base Case scenario is hidden DKK. Compared to the current market price of 300.2 DKK, Novo Nordisk A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVO B Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
98
vs Industry
18
Median 3Y
10.9
Median 5Y
9.9
Industry
2.6
Forward
4.3
More Details
13
P/E
P/E
Price to Earnings
13
vs History
96
vs Industry
21
Median 3Y
34.9
Median 5Y
29.4
Industry
21.7
Forward
12.7
More Details
10.9
P/OCF
P/OCF
Price to OCF
10.9
vs History
98
vs Industry
23
Median 3Y
25.1
Median 5Y
23.1
Industry
16.6
More Details
13.6
P/FCFE
P/FCFE
Price to FCFE
13.6
vs History
92
vs Industry
24
Median 3Y
32.9
Median 5Y
24.5
Industry
22.5
More Details
7.9
P/B
P/B
Price to Book Value
7.9
vs History
98
vs Industry
3
Median 3Y
24.2
Median 5Y
20.2
Industry
2.3
More Details
4.4
EV/S
EV/S
Enterprise Value to Sales
4.4
vs History
98
vs Industry
16
Median 3Y
11
Median 5Y
9.9
Industry
2.9
Forward
4.5
More Details
5.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.4
vs History
96
vs Industry
22
Median 3Y
13.1
Median 5Y
11.9
Industry
5.5
More Details
9.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.1
vs History
96
vs Industry
25
Median 3Y
23.3
Median 5Y
21.4
Industry
13.1
Forward
9.2
More Details
10.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.6
vs History
96
vs Industry
25
Median 3Y
25.6
Median 5Y
23.4
Industry
16.6
Forward
10.6
More Details
11.3
EV/OCF
EV/OCF
Enterprise Value to OCF
11.3
vs History
98
vs Industry
23
Median 3Y
25
Median 5Y
23.1
Industry
15.8
More Details
23
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23
vs History
93
vs Industry
15
Median 3Y
33.1
Median 5Y
29.7
Industry
19.1
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
98
vs Industry
13
Median 3Y
9.6
Median 5Y
8.7
Industry
1.9
More Details

Multiples Across Competitors

NOVO B Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13 9.1 10.6
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
251.9B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
211.7B GBP 4.9 30 108.3 158.5
CH
Novartis AG
SIX:NOVN
206.7B CHF 4.6 17.9 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
FR
Sanofi SA
PAR:SAN
102.1B EUR 1.5 7.4 6.7 6.7
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
CSE:NOVO B
Average P/E: 21.6
13
4%
3.2
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
17.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
FR
Sanofi SA
PAR:SAN
7.4
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBITDA: 398.4
9.1
2%
4.5
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
FR
Sanofi SA
PAR:SAN
6.7
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBIT: 1 708.3
10.6
1%
10.6
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3
FR
Sanofi SA
PAR:SAN
6.7
15%
0.4

See Also

Summary
NOVO B intrinsic value, competitors valuation, and company profile.
DCF Valuation
NOVO B stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NOVO B stock valuation using valuation multiples.
Wall Street Estimates
NOVO B price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NOVO B stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.